TECHNOLOGY: Cell therapy
A two-part CAR T cell system could enable flexible antigen targeting and tunable control of on- and off-target toxicities to treat liquid and solid cancers. The split, universal and programmable (SUPRA) CAR system consists of: a leucine zipper-based linker protein with a specific antigen-binding site on one end and a CAR binding site on the other; and CAR T cells engineered to express...